MicroRNA与神经胶质瘤血管生成及替莫唑胺化疗耐药关系的研究进展  

Research progress on the role of microRNA in angiogenesis and temozolomide resistance in gliomas

作　　者：毛小元[1,2] 周宏灏[1,2] 刘昭前[1,2] 

机构地区：[1]中南大学湘雅医院临床药理研究所,湖南长沙410008 [2]中南大学临床药理研究所/湖南省遗传药理学重点实验室,湖南长沙410078

出　　处：《中国生化药物杂志》2016年第3期1-4,共4页Chinese Journal of Biochemical Pharmaceutics

基　　金：国家高技术研究发展计划(863计划;2012AA02A517);国家自然科学基金(81173129;81373490)

摘　　要：肿瘤血管生成对于神经胶质瘤的生长、侵袭和转移至关重要。化疗是胶质瘤治疗不可缺少的治疗手段,替莫唑胺是最主要的治疗神经胶质瘤的一线药物,但使用一段时间后,替莫唑胺往往会出现明显耐药现象。MicroRNA(miRNA)是一类小片段的非编码RNA,在调控基因表达的转录后水平中发挥重要作用。国内外研究发现,miRNA对神经胶质瘤血管生成及替莫唑胺化疗耐药具有重要的调节作用。本文就miRNA与神经胶质瘤血管生成及替莫唑胺化疗耐药关系的研究进展做一综述。Angiogenesis plays a critical role in the glioma cell proliferation,invasion and metastasis. Additionally,chemotherapy is an important therapeutic strategy for the treatment of glioma patients. Temozolomide is a commonly used alkylating agent for treating glioma in clinical practices.However,the major problem is acquired resistance. MicroRNAs（ miRNAs） are a kind of small non-coding RNAs,which is important to regulate the post-transcription of gene expression. Several research groups have revealed that the alterations of miRNA are linked with tumor angiogenesis and drug resistance in gliomas. Currently,we made a systematic review of the role of miRNA in the angiogenesis and TMZ resistance in gliomas.

关 键 词：MIRNA 神经胶质瘤 血管生成 替莫唑胺 耐药 

分 类 号：R739.4[医药卫生—肿瘤]